Advertisement
Australia markets closed
  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     
  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     
  • AUD/USD

    0.6416
    -0.0009 (-0.14%)
     
  • OIL

    83.03
    +0.30 (+0.36%)
     
  • GOLD

    2,397.90
    -0.10 (-0.00%)
     
  • Bitcoin AUD

    101,171.66
    +6,142.55 (+6.46%)
     
  • CMC Crypto 200

    1,337.31
    +24.68 (+1.88%)
     
  • AUD/EUR

    0.6026
    -0.0004 (-0.07%)
     
  • AUD/NZD

    1.0893
    +0.0018 (+0.17%)
     
  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     
  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     
  • FTSE

    7,830.78
    -46.27 (-0.59%)
     
  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     
  • DAX

    17,676.66
    -160.74 (-0.90%)
     
  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

Is Gilead Sciences a Buy After Its Disappointing Q2 Results?

Is Gilead Sciences a Buy After Its Disappointing Q2 Results?

Gilead Sciences (NASDAQ: GILD) beat Wall Street estimates when the big biotech announced its first-quarter results in late April. Last week, Gilead announced second-quarter results that were below analysts' expectations. Gilead has been in the news quite a bit in recent months thanks to the clinical success for its COVID-19 therapy remdesivir.